Maykin Ho, Ph.D.
Maykin Ho has more than 30 years of experience in the healthcare and finance industries. She is currently a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong.
Maykin is a retired partner of the Goldman Sachs Group, where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking. Prior to Goldman Sachs, she held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Maykin currently serves on the board of directors for Agios Pharmaceuticals, BioMarin Pharmaceutical Inc., Fibrogen Inc., GRAIL, the Aaron Diamond AIDS Research Center and the Institute for Protein Innovation.
Maykin holds a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business at Duke University.